CIDP, or chronic inflammatory demyelinating polyneuropathy, is classified as an autoimmune disease of the peripheral nerves.1PubMed Central. Deciphering immune mechanisms in chronic inflammatory demyelinating polyneuropathies The immune system mounts an attack against the myelin sheath, the insulating coating that wraps around nerve fibers and allows electrical signals to travel quickly from the brain to the limbs and back. What makes CIDP particularly insidious is that the damage is not a one-time event. The disease either progresses steadily or relapses over months and years, gradually undermining nerve function in ways that can become permanent if left untreated.
What the Immune System Actually Targets
To understand how CIDP damages nerves, it helps to know a little about nerve anatomy. Peripheral nerves are long cables running from the spinal cord to the muscles and skin. Each nerve fiber is wrapped in segments of myelin, produced by specialized cells called Schwann cells. Between each myelin segment sits a tiny gap called the node of Ranvier, where the electrical signal “jumps” from one segment to the next. This jumping, called saltatory conduction, is what makes nerve signals fast. CIDP disrupts this process by attacking either the myelin itself or the junctions where myelin attaches to the nerve fiber.
In recent years, researchers have identified specific antibodies in CIDP patients that target proteins at the node of Ranvier. These autoantibodies go after molecules called neurofascin-155, contactin-1, and contactin-associated protein 1, all of which are critical for anchoring myelin loops to the nerve fiber at the paranode, the zone immediately flanking each node.2PubMed Central. Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance When these antibodies bind to their targets, they physically peel the terminal myelin loops away from the nerve surface. Electron microscopy of nerve biopsies from patients with anti-neurofascin-155 and anti-contactin-1 antibodies shows this detachment clearly, and the pattern is distinct from the classic macrophage-driven stripping of myelin seen in other forms of nerve inflammation.3Journal of Neurology, Neurosurgery & Psychiatry. Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 and anti-contactin-1 antibodies
A particular subclass of antibody, IgG4, appears especially destructive at the paranodes. In skin biopsies from CIDP patients, IgG4 autoantibodies were linked to visible structural changes at paranodal junctions, and evidence from at least one patient showed these antibodies could penetrate the paranode and break apart the protein complex that holds the junction together.4PubMed. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype The result is that signals leak, slow down, or fail to cross the gap entirely. Patients experience progressive weakness and numbness, typically starting in the hands and feet and moving inward.
How the Complement System Amplifies the Damage
Autoantibodies alone do not tell the whole story. The complement system, a cascade of proteins the body normally uses to tag and destroy bacteria, gets activated inappropriately in CIDP and piles onto the damage already caused by antibodies. A 2022 study found that blood levels of multiple activated complement proteins were markedly elevated in CIDP patients compared to healthy individuals. Importantly, patients with active, unstable disease had even higher levels of the terminal complement components C5a and the soluble terminal complement complex than patients whose disease was stable or in remission.5PubMed Central. Aberrant Complement Activation Is a Prominent Feature of Chronic Inflammatory Demyelinating Polyneuropathy
What complement activation means in practice is that the immune assault goes beyond simply loosening myelin. When complement reaches its final step, it forms what is called the membrane attack complex, which punches holes in cell membranes. In one case report, a CIDP patient with antibodies against a myelin lipid called LM1 showed complement deposition directly on the compact myelin sheath, alongside macrophage infiltration within the nerve fascicles.6PubMed Central. The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies So complement is not just a bystander. It actively participates in tearing apart the myelin coating.
T Cells and Macrophages Add Another Layer
The antibody and complement story is strongest in what is called “typical” CIDP, the form that causes symmetric weakness in both the arms and legs. But CIDP has several subtypes, and not all of them rely on the same immune mechanism. Research suggests that in Lewis-Sumner syndrome, a variant of CIDP where symptoms affect one side of the body or individual limbs rather than both sides equally, the damage is driven more by macrophages and T cells than by circulating antibodies.7PubMed Central. Atypical chronic inflammatory demyelinating polyradiculoneuropathy: recent advances on classification, diagnosis, and pathogenesis
Evidence of T cell involvement across CIDP more broadly comes from studies showing that patients have heightened T cell reactivity compared to healthy controls. CIDP patients showed significantly increased spontaneous production of the inflammatory signaling molecule interferon-gamma, and a significant proportion also showed T cell responses to a specific myelin protein fragment called PMP-22.8Journal of Neurology, Neurosurgery & Psychiatry. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy The picture that emerges is one where multiple arms of the immune system converge on peripheral nerves, with the exact mix varying between patients and subtypes.
Why the Damage Gets Worse Over Time
A frustrating reality of CIDP is that it does not just destroy myelin. Over time, the nerve fibers themselves, the axons, degenerate. This is called secondary axonal loss, and it is a common feature of demyelinating neuropathies. The process correlates with long-lasting disability in patients.9PubMed Central. New evidence for secondary axonal degeneration in demyelinating neuropathies Think of it this way: if the myelin sheath is the insulation on an electrical wire, losing the insulation is bad, but the wire can still carry a signal, however poorly. Lose the wire itself, and recovery becomes much harder.
This distinction matters clinically. A study of CIDP patients found that muscle weakness was significantly worse further from the body, in the hands and feet versus the shoulders and hips, a pattern consistent with the longest nerve fibers being most vulnerable to secondary axonal damage on top of primary demyelination.10PubMed. Length-dependent weakness and electrophysiological signs of secondary axonal loss in chronic inflammatory demyelinating polyradiculoneuropathy A prospective study tracking patients over time confirmed that axonal damage markers, not demyelination markers, were the ones most strongly correlated with clinical disability at every disease stage. This held true both at first diagnosis and in advanced disease.11PubMed. Axonal damage determines clinical disability in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): A prospective cohort study of different CIDP subtypes and disease stages
The practical implication is that early treatment matters enormously. Myelin can regenerate to some degree if the immune attack is brought under control. But once axons are lost, recovery is limited. This is why neurologists push to diagnose and treat CIDP before irreversible nerve fiber damage accumulates.
How CIDP Is Diagnosed
Diagnosing CIDP is harder than it sounds, partly because no single test proves the disease is present. The diagnosis remains fundamentally a clinical one, built from a combination of symptoms, examination findings, and supportive tests. Nerve conduction studies are the most reliable and widely available tool, looking for signs that electrical signals are traveling through nerves abnormally slowly, a hallmark of impaired saltatory conduction caused by demyelination.12Brain. Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy
A spinal tap often shows elevated protein in the cerebrospinal fluid with a normal white cell count, a pattern found in up to about 90% of patients with typical CIDP.12Brain. Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy But this finding is not specific to CIDP. In one study examining patients referred with a CIDP diagnosis who turned out not to have the disease, half of them also had elevated spinal fluid protein, though the elevations were generally mild.13PubMed. CIDP diagnostic pitfalls and perception of treatment benefit And nerve conduction studies in those misdiagnosed patients often showed demyelinating features too, just ones better explained by a different condition. Misdiagnosis is a recognized problem in CIDP, and it runs in both directions. Patients may be incorrectly labeled as having CIDP, and patients who actually have it may go undiagnosed for months or years.
Imaging is increasingly playing a role. Magnetic resonance neurography and high-resolution nerve ultrasound can detect swelling of nerve trunks. In one study, CIDP patients had brachial plexus nerve cross-sectional areas roughly double those of healthy controls, and the two imaging techniques agreed well with each other.14PubMed Central. Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Comparative Study of Magnetic Resonance Neurography and High-Resolution Nerve Ultrasound in the Assessment of Brachial Plexus While imaging alone does not confirm CIDP, visible nerve enlargement in the right clinical context adds confidence to the diagnosis.
The Diabetes Problem
One of the trickiest diagnostic scenarios involves patients who have both diabetes and symptoms that could be CIDP. Diabetic polyneuropathy, the nerve damage caused by chronically high blood sugar, shares overlapping clinical and electrodiagnostic features with CIDP. Both conditions cause numbness, weakness, and abnormal nerve conduction studies, which means CIDP can easily be missed in a patient already assumed to have diabetic nerve damage.15PubMed Central. CIDP and other inflammatory neuropathies in diabetes — diagnosis and management
When CIDP does occur alongside diabetes, the combination tends to be worse than either alone. The pre-existing axonal damage from diabetic polyneuropathy means that the additional immune-mediated assault of CIDP hits nerves that are already compromised, and the clinical presentation and resulting disability may be more severe as a result.16PubMed. The overlap of diabetic and inflammatory neuropathies: Epidemiology, possible mechanisms, and treatment implications Nerve ultrasound may help tease the two apart. In one study, a composite scoring system combining ultrasound nerve size measurements with a clinical disability scale distinguished CIDP-with-diabetes from pure diabetic polyneuropathy with high accuracy.17Scientific Reports. Nerve ultrasound helps to distinguish CIDP patients with diabetes from patients with diabetic polyneuropathy Getting this distinction right is not academic. If the treatable autoimmune component goes unrecognized, the patient misses out on therapies that could slow or reverse their decline.
How Treatment Tames the Immune Attack
Because CIDP is autoimmune, treatment focuses on dampening the immune system’s assault on peripheral nerves. The three established first-line therapies are intravenous immunoglobulin (IVIg), corticosteroids, and plasma exchange. Each works through a different angle of immune modulation.
IVIg is perhaps the best studied. It delivers a large dose of pooled human antibodies, which paradoxically tamp down the recipient’s own harmful immune responses. One mechanism involves restoring expression of an inhibitory receptor on B cells and monocytes. In CIDP patients, this receptor appears underexpressed, which may allow self-reactive B cells to thrive. Clinically effective IVIg therapy has been shown to upregulate this receptor, essentially putting a brake on the overactive immune cells.18PubMed. Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy
Plasma exchange works on a more direct principle. If circulating autoantibodies are causing the damage, physically removing them from the blood should help. The approach has been used for decades, and evidence supports short-term improvement in many patients, though the benefits tend to fade within weeks because the immune system keeps producing new autoantibodies.19PubMed Central. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy This means plasma exchange is often used as a bridge or in acute flares rather than as a long-term standalone treatment.
Corticosteroids suppress the immune system broadly and are effective for many CIDP patients, but long-term use carries well-known side effects including weight gain, bone thinning, and elevated blood sugar. The choice among these first-line treatments depends on the individual patient’s subtype, severity, tolerance for side effects, and practical factors like access to infusion centers.
Newer Targeted Therapies
For patients who do not respond adequately to first-line treatments, the search for more precise therapies is advancing. One promising approach targets the neonatal Fc receptor (FcRn), a protein that normally recycles IgG antibodies and keeps their levels high in the blood. Blocking this receptor accelerates the clearance of all IgG, including the harmful autoantibodies driving CIDP.
Efgartigimod, an FcRn inhibitor, showed strong results in a large clinical trial. In the open-label first stage, about two-thirds of participants showed confirmed evidence of clinical improvement. Those who improved then entered a randomized stage comparing efgartigimod against placebo, where the drug reduced the risk of relapse by 61% compared to placebo.20PubMed Central. Evaluation and treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy This is a meaningful shift from the blunt immunosuppression of corticosteroids toward therapies that are designed around the specific mechanisms of antibody-mediated nerve damage.
The growing understanding of complement’s role in CIDP has also opened up potential treatment targets. If complement activation is driving a significant portion of the nerve damage, complement inhibitors already approved for other conditions could theoretically be repurposed. Research on complement-targeted therapies for CIDP is still in its earlier stages, but the evidence that complement levels track with disease activity provides a biological rationale.5PubMed Central. Aberrant Complement Activation Is a Prominent Feature of Chronic Inflammatory Demyelinating Polyneuropathy
Genetic Susceptibility
CIDP is not inherited in any straightforward way, but genetics appear to influence who develops it. A study of Korean patients found that a specific immune gene variant, HLA-DRB1*04, was dramatically overrepresented among CIDP patients compared to controls, appearing in about 28% of patients versus under 3% of the general population. The odds of having this variant were roughly 14 times higher in CIDP patients.21PubMed Central. Genetic susceptibility of human leukocyte antigen alleles in chronic inflammatory demyelinating polyneuropathy in Korean patients HLA genes shape which fragments of proteins the immune system notices and reacts to, so a variant that predisposes to CIDP may cause the immune system to treat normal nerve proteins as threats.
This does not mean that carrying DRB1*04 guarantees CIDP. The vast majority of people with that variant never develop the disease. Like most autoimmune conditions, CIDP probably requires a combination of genetic susceptibility and some triggering event, whether that is an infection, a vaccination, surgery, or something that has yet to be identified. The genetic findings do help explain why CIDP clusters in certain families and why some ethnic groups may have different rates of the disease, though population-specific studies like this one cannot be automatically generalized to other groups.
What Animal Models Have Taught Us
Much of what researchers know about how autoimmune neuropathies develop comes from animal models, where the immune system can be deliberately turned against peripheral nerve proteins under controlled conditions. These models have provided insights into which components of the immune response are necessary for demyelination, how the blood-nerve barrier breaks down, and how different types of immune cells coordinate their attack.22PubMed Central. Animal models of autoimmune neuropathy The relevance to human CIDP is imperfect, since most animal models produce acute rather than chronic disease, but they remain one of the few ways to study the early stages of immune-mediated nerve damage before patients typically come to clinical attention. Ongoing refinements in these models are helping researchers test targeted treatments before they move into human trials.